Gene patenting ruling unlikely to really impact oncology care

Gene patenting ruling unlikely to really impact oncology care
The Supreme Court decision in Association for Molecular Pathology v. Myriad is not likely to have much immediate impact the practice of oncology, according to a special communication published online June 13 in the Journal of Clinical Oncology.

(HealthDay)—The Supreme Court decision in Association for Molecular Pathology v. Myriad is not likely to have much immediate impact the practice of oncology, according to a special communication published online June 13 in the Journal of Clinical Oncology.

Kenneth Offit, M.D., M.P.H., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues reviewed previous court cases and , as well as earlier rulings in the course of this case.

The authors note that, for most common other than BRCA, which is at the center of this case, genetic testing is not restricted by exclusive patent enforcement. Isolated DNA patents are already becoming obsolete with the advent of next generation sequencing technologies. Additionally, methods patents based on DNA sequence have already been weakened by earlier rulings. Patents related to new drug development usually involve cellular methods and thus will not likely be impacted by this case.

"It is important that judicial and legislative actions in this area maximize genomic discovery while also ensuring patients' access to personalized cancer care," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

High court ruling on gene patents lifts Myriad

Jun 13, 2013

Shares of diagnostic test maker Myriad Genetics Inc. are jumping Thursday after the Supreme Court issued a mixed ruling in a case involving the company's patents on genes at the center of its tests for increased risk of bre ...

Recommended for you

Discovery could lead to new cancer treatment

Aug 29, 2014

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

User comments